AgmaPure is a trademarked form of agmatine sulfate. Agmatine sulfate is a salt of agmatine, a product of arginine being broken down.
Most agmatine sulfate used in health supplements contains impurities. These impurities are mostly putrescine, an odorous chemical created when agmatine undergoes hydrolysis.
In contrast, AgmaPure is created through a fermentation process that minimizes putrescine, making AgmaPure a purer agmatine sulfate form.
Because it is pure agmatine sulfate, AgmaPure yields the same benefits as agmatine sulfate. Most agmatine sulfate studies have been performed in cell cultures or on animals. But, these studies still indicate AgmaPure’s potential benefits.
AgmaPure increases muscular storage of glycogen and water. This could increase muscular energy and enhance muscle appearance and pump.
In one preliminary study, agmatine injections lowered rat’s blood glucose levels and raised beta-endorphin secretion. Further research indicates beta-endorphin encourages skeletal muscle tissue to absorb blood glucose.
AgmaPure also acts as a vasodilator. It encourages nitric oxide production by restricting action of the enzymes that inhibit nitric oxide production.
Growth hormone and luteinizing hormone secretion increase after AgmaPure supplementation.
An animal study showed when agmatine enters the brain it rapidly stimulates luteinizing hormone release. Similarly, when agmatine-containing peptides were injected into cows, growth hormone secretion increased significantly.
AgmaPure promotional literature reports agmatine usually causes no negative side effects even with high doses. However, current research on AgmaPure and agmatine sulfate is insufficient to be sure it causes no major side effects.
In a study assessing agmatine sulfate’s pain-reducing effects, some study participants reported mild nausea and diarrhea. These side effects occurred only in participants taking the highest agmatine sulfate dosage, 3.56 g per day. No additional side effects were reported, and no adverse events occurred. Consequently, AgmaPure’s most likely side effects are mild gastrointestinal distress.
The lack of human agmatine sulfate research means effective AgmaPure dosages haven’t been firmly established. But, agmatine sulfate supplements usually contain between 500 and 1000 mg per serving.
Research shows people have tolerated up to 2.67 g agmatine sulfate per day without side effects. Consequently, an equal or lesser AgmaPure dose is likely to be equally well tolerated.
-  Morrissey, JJ, and S Klahr. “Agmatine activation of nitric oxide synthase in endothelial cells.” Proceedings of the Association of American Physicians. 109.1 (1997): 51-7.
-  Mella, C, F Martinez, et al. “Expression and localization of an agmatinase-like protein in the rat brain.” Histochemistry and Cell Biology. 134.2 (2010): 137-44.
-  Dong, Yiying. “AgmaPure.”
-  Hwang, SL, IM Liu, TF Tzeng, and JT Cheng. “Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats.” Diabetologia. 48.4 (2005): 767-75
-  Khan, S, AA Evans, S Hughes, and ME Smith. “Beta-endorphin decreases fatigue and increases glucose uptake independently in normal and dystrophic mice.” Muscle & Nerve. 31.4 (2005): 481-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15704144.
-  Gao, Y, B Gumusel, et al. “Agmatine: a novel endogenous vasodilator substance.” Life Sciences. 57.8 (1995): PL83-6.
-  Kalra, SP, E Pearson, A Sahu, and PS Kalra. “Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone release in vitro.” Neuroscience Letters. 194.3 (1995): 165-8.
-  Roberge, S, HE Johnson, M Zarandi, AV Schally, and JJ Reeves. “Evaluation of the biological potency of new agmatine analogs of growth hormone-releasing hormone in the bovine.” Proceedings of the Society for Experimental Biology and Medicine. 200.1 (1992): 109-14.
-  Examine.com. “Agmatine.” 2013 Jul 15.
-  Keynan, O, Y Mirovsky, et al. “Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial.” Pain Medicine. 11.3 (2010): 356-68.